Earnings summaries and quarterly performance for Corvus Pharmaceuticals.
Executive leadership at Corvus Pharmaceuticals.
Board of directors at Corvus Pharmaceuticals.
Research analysts who have asked questions during Corvus Pharmaceuticals earnings calls.
Aydin Huseynov
Ladenburg Thalmann
4 questions for CRVS
Also covers: ARDX, CAPR, CLRB +3 more
Jeff Jones
Oppenheimer & Co. Inc.
4 questions for CRVS
Also covers: ABEO, CLRB, CMMB +8 more
Graig Suvannavejh
Mizuho Securities
3 questions for CRVS
Also covers: ADAP, ADVM, ALEC +12 more
LW
Li Wang Watsek
Cantor Fitzgerald
3 questions for CRVS
Also covers: AFMD, ALXO, ARVN +7 more
JS
Jiale Song
Jefferies Financial Group Inc.
2 questions for CRVS
Also covers: ACRS, CTMX, CVAC +12 more
XL
Xun Lee
H.C. Wainwright & Co., LLC
2 questions for CRVS
Also covers: ATEC, CTSO, EDAP +2 more
CS
Craig Suvanevej
Mizuho Securities USA LLC
1 question for CRVS
RS
Roger Song
Jefferies
1 question for CRVS
Also covers: AADI, AKBA, ALT +14 more
Recent press releases and 8-K filings for CRVS.
Corvus Pharmaceuticals Provides Soquelitinib Pipeline Update
CRVS
New Projects/Investments
Guidance Update
- Corvus Pharmaceuticals' lead asset, soquelitinib, a novel first-in-class oral ITK inhibitor, is currently in a Phase 3 registrational trial for peripheral T-cell lymphoma (PTCL), with interim analysis expected by year-end 2026.
- The company plans to initiate a Phase 2 clinical trial for soquelitinib in atopic dermatitis (AD) in Q1 2026, with data anticipated in approximately 18 months.
- Clinical data for soquelitinib in AD demonstrated a favorable safety profile and efficacy, with 75% of patients achieving EASI-75 and 33% achieving IGA 0/1 after 8 weeks of treatment in Cohort 4, showing superiority over placebo.
- Corvus also plans to start two Phase 2 proof-of-concept studies this year in asthma and HS.
1 day ago
Corvus Pharmaceuticals Updates on Soquelitinib Pipeline Progress
CRVS
New Projects/Investments
Product Launch
- Corvus Pharmaceuticals' lead asset, soquelitinib, is a novel oral therapy currently in a Phase III registrational trial for peripheral T-cell lymphoma (PTCL), with interim analysis expected by year-end 2026.
- A Phase II clinical trial for soquelitinib in atopic dermatitis (AD) is set to begin in Q1 2026, with data anticipated in approximately 18 months.
- Soquelitinib has demonstrated promising results in AD, with 75% of patients achieving EASI-75 and 33% achieving IGA 0/1 after 8 weeks of treatment in Cohort 4, showing a favorable safety profile and durable responses.
- The company plans to initiate two additional Phase II proof-of-concept studies for soquelitinib in asthma and HS in 2026.
1 day ago
Corvus Pharmaceuticals Announces Public Offering of Common Stock
CRVS
New Projects/Investments
- On January 21, 2026, Corvus Pharmaceuticals, Inc. entered into an underwriting agreement for the sale and issuance of 7,900,677 shares of its common stock at a public offering price of $22.15 per share.
- The underwriters fully exercised an option on January 22, 2026, to purchase an additional 1,185,101 shares, bringing the total shares to be issued to 9,085,778.
- The offering is expected to close on January 23, 2026, with estimated net proceeds to the company of approximately $188.3 million after deducting underwriting discounts, commissions, and offering expenses.
- The company intends to use the net proceeds for working capital and general corporate purposes, including funding its Phase 3 T cell lymphoma and Phase 2 atopic dermatitis, hidradenitis suppurativa, and asthma clinical trials.
Jan 23, 2026, 11:06 AM
Corvus Pharmaceuticals Announces Pricing of Upsized Public Offering
CRVS
New Projects/Investments
- Corvus Pharmaceuticals announced the pricing of an upsized underwritten public offering of 7,900,677 shares of its common stock at $22.15 per share.
- The offering is expected to generate gross proceeds of approximately $175.0 million.
- The company has granted the underwriters a 30-day option to purchase up to an additional 1,185,101 shares.
- Net proceeds are anticipated to be used for working capital and general corporate purposes, including capital expenditures and research and development for its Phase 3 T cell lymphoma, and Phase 2 atopic dermatitis, hidradenitis suppurativa, and asthma clinical trials.
- The offering is expected to close on or about January 23, 2026.
Jan 22, 2026, 3:53 AM
Corvus Pharmaceuticals Commences Public Offering
CRVS
- Corvus Pharmaceuticals, Inc. has commenced an underwritten public offering of $150,000,000 of shares of its common stock and pre-funded warrants.
- The company expects to grant the underwriters a 30-day option to purchase up to an additional $22,500,000 of shares of common stock.
- Corvus Pharmaceuticals expects to use the net proceeds for working capital and general corporate purposes, including capital expenditures and research and development for its Phase 3 T cell lymphoma, and Phase 2 atopic dermatitis, hidradenitis suppurativa and asthma clinical trials.
- Jefferies and Goldman Sachs & Co. LLC are acting as lead book-running managers for the offering.
Jan 20, 2026, 9:01 PM
Corvus Pharmaceuticals Presents Positive Phase 1 Results for Socalitinib in Atopic Dermatitis and Outlines Future Clinical Plans
CRVS
Product Launch
New Projects/Investments
- Corvus Pharmaceuticals announced positive results from its Phase 1 clinical trial of Socalitinib for atopic dermatitis, highlighting it as a potential first-in-class oral drug.
- In Cohort 4, 75% of patients achieved EASI 75, 25% achieved EASI 90, and 33% achieved IGA 0/1, with a mean EASI score reduction of 72% at eight weeks.
- Socalitinib demonstrated durable responses and comparable efficacy in patients with and without prior systemic therapies.
- The company plans to initiate a Phase 2 randomized placebo-controlled trial for Socalitinib in atopic dermatitis in Q1 2026, enrolling 200 patients, and also expects to start Phase 2 trials in hidradenitis suppurativa and asthma in 2026.
- An interim analysis from the ongoing Phase 3 lymphoma study is anticipated later in 2026.
Jan 20, 2026, 1:00 PM
Corvus Pharmaceuticals Presents Positive Phase I Clinical Trial Results for Soquelitinib in Atopic Dermatitis
CRVS
New Projects/Investments
- Corvus Pharmaceuticals presented positive results from its phase I clinical trial of Soquelitinib for atopic dermatitis, positioning it as a first-in-class oral drug.
- In Cohort 4, Soquelitinib achieved a mean percent reduction in EASI score of 72% at eight weeks (versus 40% for placebo, p-value 0.035), with 75% of patients achieving EASI 75.
- The drug demonstrated durable responses and efficacy in patients who had received prior systemic therapies, supported by a novel mechanism of action involving immune system rebalancing and Treg induction.
- Corvus plans to initiate a phase II randomized placebo-controlled trial in atopic dermatitis in Q1 2026, with additional phase II trials in hidradenitis suppurativa and asthma also planned for 2026, alongside an ongoing phase III trial in relapsed peripheral T-cell lymphoma.
- Soquelitinib is protected by composition of matter patents through 2042 and targets the atopic dermatitis market, which is projected to grow to $170 billion by 2030.
Jan 20, 2026, 1:00 PM
CRVS Presents Positive Phase I Clinical Trial Results for Socalitinib in Atopic Dermatitis
CRVS
New Projects/Investments
Product Launch
- Socalitinib's Phase I clinical trial for atopic dermatitis (AD) demonstrated positive results in Cohort 4, with 75% of patients achieving EASI 75, 25% achieving EASI 90, and 33% achieving IGA 0/1, alongside a mean percent reduction in EASI score of 72% at eight weeks of treatment.
- The drug appeared to be safe and effective, showing durable responses and no dose-limiting toxicities in prior studies, with a low adverse event rate in AD patients.
- Socalitinib was active in patients who had received prior systemic therapies, exhibiting similar efficacy in both systemic treatment-naive and experienced patients.
- The company plans to initiate a Phase 2 randomized placebo-controlled trial in AD in Q1 2026, enrolling 200 patients across four cohorts, and also has planned Phase 2 trials for hidradenitis suppurativa and asthma in 2026.
Jan 20, 2026, 1:00 PM
Corvus Pharmaceuticals Announces Positive Soquelitinib Phase 1 Clinical Trial Data for Atopic Dermatitis
CRVS
New Projects/Investments
- Corvus Pharmaceuticals announced positive results from cohort 4 of its randomized, blinded, placebo-controlled Phase 1 clinical trial for soquelitinib in patients with moderate to severe atopic dermatitis.
- The cohort 4 data demonstrated favorable safety and efficacy, with 75% of soquelitinib patients achieving EASI 75, 25% achieving EASI 90, and 33% achieving IGA 0/1, compared to 20%, 0%, and 0% for the placebo group, respectively. The mean percent reduction in EASI for soquelitinib patients in cohort 4 was 72% at day 56, compared to 40% for placebo patients.
- No new safety signals were observed as of January 15, 2026, with all reported adverse events being Grade 1-2 and not leading to dose modifications or interruptions.
- Based on these positive results, the company plans to initiate a Phase 2 clinical trial for soquelitinib in Q1 2026, enrolling approximately 200 patients with moderate-to-severe atopic dermatitis.
Jan 20, 2026, 12:13 PM
Corvus Pharmaceuticals Announces Positive Soquelitinib Phase 1 Data for Atopic Dermatitis
CRVS
New Projects/Investments
- Corvus Pharmaceuticals announced positive results from Cohort 4 of its randomized, blinded, placebo-controlled Phase 1 clinical trial for soquelitinib in moderate to severe atopic dermatitis on January 20, 2026.
- The Cohort 4 data demonstrated favorable safety and efficacy, with 75% of soquelitinib patients achieving EASI 75, 25% achieving EASI 90, and 33% achieving IGA 0/1.
- The company plans to initiate a Phase 2 clinical trial for soquelitinib in patients with moderate to severe atopic dermatitis in the first quarter of 2026.
- No new safety signals were observed in Cohort 4, and all reported adverse events were Grade 1-2, not requiring dose modifications or interruptions.
Jan 20, 2026, 12:00 PM
Quarterly earnings call transcripts for Corvus Pharmaceuticals.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more